CoChat

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

Chagas, Marcos Hortes N, Zuardi, Antonio W, Tumas, Vitor, Pena-Pereira, Márcio Alexandre, Sobreira, Emmanuelle T, Bergamaschi, Mateus M, dos Santos, Antonio Carlos, Teixeira, Antonio Lucio, Hallak, Jaime EC, Crippa, José Alexandre S · 2014 · Journal of Psychopharmacology

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Introduction: Parkinson’s disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. Methods: From a sample of 119 patients consecutively evaluated in a specialized movement disorders outpatient clinic, we selected 21 PD patients without dementia or comorbid psychiatric conditions. Participants were assigned to three groups of seven subjects each who were treated with placebo, cannabidiol (CBD) 75 mg/day or CBD 300 mg/day. One week before the trial and in the last week of treatment participants were assessed in respect to (i) motor and general symptoms score (UPDRS); (ii) well-being and quality of life (PDQ-39); and (iii) possible neuroprotective effects (BDNF and H 1 -MRS). Results: We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H 1 -MRS measures. However, the groups treated with placebo and CBD 300 mg/day had significantly different mean total scores in the PDQ-39 ( p = 0.05). Conclusions: Our findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881114550355

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Zuardi AW, 1995, J Clin Psychiatry, 56, 485

Cited by

See all 365

Metadata

Authors
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S.
Affiliations
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
  • Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
  • Universidade de São Paulo (BR)
  • Laboratório Interdisciplinar de Investigação Médica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Venue
Journal of Psychopharmacology
Published
2014-09-18
Volume
28
Issue
11
Pages
1088-1098
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2141929843
Cited by
365
References
26
Citations by year
2026: 18 · 2025: 24 · 2024: 39 · 2023: 44 · 2022: 60 · 2021: 33 · 2020: 48 · 2019: 38 · 2018: 21 · 2017: 23 · 2016: 11 · 2015: 6
FWCI
9.72
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
cannabidiol, Parkinson's disease, endocannabinoid system, neuroprotection, quality of life, brain-derived neurotrophic factor, placebo comparison, dopaminergic neuron loss
MeSH terms
Aged, Aged, 80 and over, Aspartic Acid, Cannabidiol, Creatine, Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease, Putamen, Quality of Life, Severity of Illness Index, Treatment Outcome, Neuroprotective Agents, Brain-Derived Neurotrophic Factor, Proton Magnetic Resonance Spectroscopy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. https://app.cochat.ai/papers/10.1177/0269881114550355
The paper
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881114550355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.